Gamma Secretase Inhibitor Drug Class List

« Back to Dashboard

Drugs in Drug Class: Gamma Secretase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-001	Nov 27, 2023		DISCN	Yes	No				Y
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-001	Nov 27, 2023		DISCN	Yes	No			Y
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-002	Apr 4, 2024		RX	Yes	No
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-002	Apr 4, 2024		RX	Yes	No			Y
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-003	Apr 4, 2024		RX	Yes	Yes

Last updated: July 8, 2026

Gamma Secretase Inhibitors Market Dynamics and Patent Landscape: What Patents Protect, When Exclusivity Expires, and Where Generic/Biosimilar Risk Is Real

Executive summary

Gamma secretase inhibitors (GSIs) target presenilin-mediated intramembrane cleavage of APP and Notch. The class market is constrained by safety limits (notably GI toxicity, skin cancers from Notch pathway disruption, and drug-class tolerability). Patent estates across the class tend to be concentrated in: (1) first-generation small molecules, (2) second-generation selectivity-improved GSIs and related “Notch sparing” variants, and (3) reformulations and prodrugs. Many early GSIs have already lost effective exclusivity in key geographies, while newer candidates show shorter remaining patent tails focused on formulation, crystalline forms, and specific dosing regimens rather than core mechanism claims. In the near-to-mid term, the largest competitive pressure is expected from off-patent small-molecule competitors and “life-cycle” patent carveouts that delay narrow generic entry, not from complex biosimilar-style competition.

---

Which gamma secretase inhibitors are in the market, and what’s driving demand dynamics?

Featured snippet answer: Demand for gamma secretase inhibitors has stayed limited because the clinical profile is constrained by Notch-related class toxicities and because multiple Alzheimer’s and neurodegeneration programs shifted toward anti-amyloid antibodies and other mechanisms. Surviving commercial activity is mostly niche, trial-driven, or tied to specific regional approvals and investigational programs rather than broad, sustained chronic use.

Alzheimer’s and Notch biology: why safety caps TAM

GSIs inhibit intramembrane cleavage of APP. They also inhibit Notch processing, producing class toxicities:

• Dose-limiting diarrhea and GI events (common across GSIs).
• Skin disorders and epithelial changes consistent with impaired Notch signaling.
• Long-term risk concerns tied to pathway interference.

This safety cap affects payers and prescribers: even if efficacy endpoints are met, risk-benefit thresholds constrain adoption.

Market structure: not a mass-market chronic therapy

Compared with typical CNS chronic therapies, GSIs do not show the same broad, durable commercial footprint. The competitive landscape is shaped more by:

• Trial outcomes and stopping decisions.
• Class-level safety signals.
• Pivoting R&D into next-gen “safer” modulators (often still small molecules, sometimes partial inhibitors, and sometimes alternative targets like BACE, secretase modulators, or antibody approaches).

---

What patents protect gamma secretase inhibitors (GSIs), and how do patent estates typically break down?

Featured snippet answer: Core mechanism patents generally originate from early presenilin/gamma-secretase inhibitors and their chemical scaffolds. Later patents focus on selectivity (“Notch sparing”), specific analogs, compositions (salts, polymorphs, crystallinity), and manufacturing controls. Life-cycle protection often provides the last edge for narrow generic entry.

Patent estate archetypes in GSIs

Most enforceable IP clusters for GSIs fall into these buckets:

1) Chemical entity and analog families

• Novel scaffolds inhibiting gamma secretase.
• Claims on compounds and close structural variants.
• Typical filing patterns: early priority in the late 1990s to mid-2000s for first-wave molecules, with extended families via continuation/divisional filings where applicable.

2) Mechanism and functional claims

• Use of presenilin inhibition to modulate APP processing.
• Method-of-treatment claims tied to Alzheimer’s disease and other indications involving APP processing.

3) Selectivity and “Notch sparing” variants

• Claims on derivatives designed to reduce Notch inhibition while preserving APP cleavage reduction.
• These are often narrower but can be valuable if supported by clinical selectivity data.

4) Pharmaceutical compositions and delivery systems

• Salts, hydrates, solvates, polymorphs, and crystal forms.
• Microencapsulation, solid dispersions, and controlled-release formulations.
• Prodrugs or improved bioavailability formulations.

5) Manufacturing and particle engineering

• Processes that define crystal form control and impurity profiles.
• Milling/jetting parameter claims for particle size distributions.

---

What is the Orange Book status for gamma secretase inhibitors, and which products have real FDA-listed patent barriers?

Featured snippet answer: The Orange Book is populated only for approved, listed drugs. For GSIs, the patent barrier picture is more relevant for any approved small-molecule member that has Orange Book listings; for most class programs that stayed investigational, there is no Orange Book framework because no FDA-approved drug exists.

How to read Orange Book risk in this class

For any GSI with an Orange Book listing:

• Patent listing coverage is often limited to drug substance or specific formulation patents, with method-of-use coverage sometimes present depending on how the product is listed.
• If a product is not marketed broadly, generic or Paragraph IV activity can still occur if there is any commercial incentive.

Practical takeaway for infringement risk

In a class where mechanism claims are old and most chemical series are off-patent, the remaining “real” barriers are often:

• Specific solid-state forms.
• Specific dosage strengths.
• Specific manufacturing-defined materials.

---

When do gamma secretase inhibitor patents expire, and what does the exclusivity timeline look like?

Featured snippet answer: The earliest GSI patents largely expired years ago in major markets, shifting the competitive focus to late-life formulation and analog patents with later expiry dates. Remaining exclusivity is usually driven by composition or specific chemical variants rather than broad method claims.

Typical timeline shape by patent type

• Early entity families: expiry often occurred in the early-to-mid 2010s for first-wave scaffolds (depending on jurisdiction and filing/priority chain).
• Late analog families: expiry rolls to mid-to-late 2010s.
• Formulation and solid-state families: can push beyond entity expiry by adding new filings around crystalline forms and composition-specific claims.
• Pediatric exclusivity and other regulatory exclusivities: can extend by limited time windows if applicable, but in practice are not the primary driver for GSIs.

---

Which gamma secretase inhibitor patents are most vulnerable to Paragraph IV challenges?

Featured snippet answer: Paragraph IV challenges are most likely against:

1. older compound families that have expired (no barrier), or
2. narrow formulation patents that can be designed around via alternative polymorphs, salts, or particle size distributions.

If a GSI has only weak composition patents left, the filing incentives for generics increase because design-around is feasible.

Typical Paragraph IV “design-around” pathways

• Choose alternative salt forms not covered by the listed claim set.
• Use different crystalline forms or controlled polymorphs.
• Change excipient systems and release profiles if claims are specific to composition.
• Adjust particle engineering targets if manufacturing claims are narrow.

---

How strong is the patent estate for gamma secretase inhibitors: freedom-to-operate versus enforceable coverage?

Featured snippet answer: Patent strength for the class is uneven. For many first-generation GSIs, enforceable coverage is gone. For select newer scaffolds and formulation-defined assets, coverage can still be meaningful but is usually narrow and concentrated in specific dosage forms or solid-state material properties.

Strength drivers that matter in litigation posture

• Claim breadth: broad structure coverage versus single polymorph or single salt.
• Evidence support: whether clinical or technical data is tightly linked to asserted advantages.
• Design-around feasibility: ability to select alternative solid forms or analogs without losing functional performance.

---

What gamma secretase inhibitors are being challenged by generic manufacturers (and what litigation patterns matter)?

Featured snippet answer: The most material litigation and competitive threats in GSIs tend to be low frequency relative to blockbuster drug classes, because many GSIs never reached wide commercial scale and many core patents expired. Where litigation exists, it often targets composition patents and specific solid-state claims.

Litigation patterns in small-molecule CNS classes

Common patterns for any ongoing disputes:

• Early dismissal motions tied to invalidity or non-infringement.
• Claim construction fights on solid-state limitations (e.g., crystallinity parameters).
• Settlement agreements that delay generic launch to a specific date tied to agreed licensing or design-around pathways.

---

How does gamma secretase inhibitor patent coverage compare with related secretase targets (BACE, sBACE, and Notch-sparing modulators)?

Featured snippet answer: GSIs face distinct IP dynamics because they intersect Notch biology. Patent estates often reflect “mechanism + chemical series” for broad coverage, then narrow down to selectivity improvements and formulation. In contrast, BACE inhibitor IP often emphasizes enzyme selectivity and brain penetration. Notch-sparing modulators overlap conceptually but are patented more narrowly around reduced Notch pathway effects.

Competitive implication

Even if a GSI molecule is off-patent, a company can still protect “functional equivalence” by switching to:

• A different pathway antagonist or secretase modulator.
• A Notch-sparing strategy with separate chemical scaffolds and different claim scope.

---

What formulations and drug delivery patents are common for GSIs, and which ones block generics?

Featured snippet answer: The highest generic blocking power typically sits in solid-state and composition patents. In GSIs, this includes salts, hydrates/solvates, polymorphs, and controlled-release or bioavailability-enhancing formulations.

Formulation patent categories that drive last-mile exclusivity

• Polymorph/crystal form patents: claims tied to specific x-ray diffraction signatures or stability windows.
• Salt patents: claims tied to exact salt identity and preparation methods.
• Combination formulations: fewer claims in this class but possible if dosing regimens include other actives.
• Manufacturing-process patents: jet milling, crystallization temperature profiles, impurity control.

---

What manufacturing/IP barriers exist for gamma secretase inhibitors beyond patents?

Featured snippet answer: IP barriers are often paired with technical barriers. For GSIs, the technical risk is that solid-state changes can affect dissolution and exposure, which can make “design-arounds” commercially non-trivial.

Common CMC/IP coupling risks

• Polymorph transitions during scale-up or storage.
• Bioavailability sensitivity to particle size and morphology.
• Impurity profiles and regulatory acceptance thresholds.

---

What generic entry risks exist for gamma secretase inhibitors by market and geography?

Featured snippet answer: Generic entry risk is highest where early compound families are expired and where remaining patents are narrow formulation or solid-state claims that are technically design-aroundable. Regions with stricter enforcement against method/manufacturing claims can slow entry even when substance patents are gone.

Geography-level dynamics

• US: If Orange Book barriers are present, Paragraph IV risk drives generic entry timing.
• EP and UK: Injunction and revocation dynamics can increase leverage for solid-state owners, especially with strong data.
• Other jurisdictions: weaker enforcement environments can accelerate “copy-and-clarify” generic launches where technical equivalence is feasible.

---

Company landscape: who owns the most relevant gamma secretase inhibitor IP, and how are they positioned?

Featured snippet answer: In the GSI space, IP is historically distributed among companies that led first-wave Alzheimer’s secretase research and later focused on formulation and selectivity. The remaining active IP tends to be portfolio-driven rather than single-product dependence.

Portfolio positioning that matters

• Owners of late-life formulation/polymorph patents can extract value even when clinical franchises stalled.
• Owners of “selectivity” analog series have better prospects for defending mechanism-related claims, but those claims are narrower.

---

Key takeaways

• Gamma secretase inhibitors remain a constrained market class due to Notch pathway toxicities, shifting competition toward selectivity-improved derivatives and life-cycle protection.
• Patent estates largely follow a predictable structure: early broad scaffolds expire, and remaining barriers increasingly center on formulation, solid-state forms, and narrow analog variants.
• Generic risk is highest where Orange Book-listed patents (if any) are formulation-limited and technically design-aroundable.
• Litigation and Paragraph IV activity in GSIs tends to focus on claim construction and solid-state limitations rather than sweeping mechanism challenges.
• Commercial relevance concentrates on any surviving approved member and on trial-stage candidates where near-term market entry depends on the ability to navigate CMC-defined IP.

---

FAQs

Which gamma secretase inhibitors have the most remaining patent life in the US and Europe?

Most remaining patent life, where applicable, is concentrated in solid-state and formulation families rather than first-generation entity patents.

Do gamma secretase inhibitor method-of-use patents delay generic entry even if drug substance is off-patent?

Yes, but only if method-of-use coverage is properly listed and enforceable in the relevant jurisdiction and claim scope is not easily designed around.

How often do gamma secretase inhibitor generics hinge on polymorph or crystal form changes?

In late-stage life-cycle estates, generics commonly hinge on alternative solid forms, stability, dissolution profile, and impurity control.

Are Notch-sparing gamma secretase modulators patented differently than classical GSIs?

Yes. Selectivity and Notch sparing strategies usually produce separate chemical series and narrower functional claim scope tied to measured selectivity.

What is the typical settlement structure in GSI-related patent cases?

When settlements occur, they often revolve around delayed launch dates tied to formulation workarounds or licensing for specific embodiments rather than broad cross-licensing of entire mechanism claims.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Trials Snapshots. U.S. Food and Drug Administration.
3. European Patent Office (EPO). Espacenet. European Patent Register.
4. U.S. Patent and Trademark Office (USPTO). Patent Public Search.
5. Bloomberg Law. Pharmaceutical patent litigation and exclusivity monitoring (platform dataset).